What is ARTMS?
ARTMS operates at the intersection of nuclear physics and clinical diagnostics. The company specializes in the development and supply of QUANTM targets, a transformative technology that empowers local cyclotrons to synthesize essential isotopes on-site. This innovation is pivotal for the healthcare industry, as it mitigates the risks associated with the transport of short-lived isotopes like Gallium-68. By integrating seamlessly into existing cyclotron infrastructure, ARTMS provides a scalable solution that enhances the availability of diagnostic tools for patient care. Their business model relies on strategic partnerships with drug innovators and medical distributors, positioning them as a critical node in the modern nuclear medicine ecosystem.
How much funding has ARTMS raised?
ARTMS has raised a total of $22M across 2 funding rounds:
Private Equity
$3M
Series A
$19M
Private Equity (2017): $3M with participation from GF Securities and Quark Venture Inc.
Series A (2020): $19M led by Deerfield Communications Inc, GF Securities Co. Ltd, and Quark Venture
Key Investors in ARTMS
Quark Venture Inc.
Quark Venture LP is a venture capital company focused on equity financing of innovative biotechnology companies with breakthrough technology platforms.
GF Securities
A prominent financial services firm providing comprehensive investment banking and capital market solutions to high-growth enterprises.
Deerfield Communications Inc
Undisclosed investor participating in the funding round.
What's next for ARTMS?
With the recent influx of capital, ARTMS is well-positioned to accelerate its commercialization strategy and deepen its penetration into international markets. The focus will likely shift toward expanding the adoption of its QUANTM technology among hospital networks and research institutions that seek to reduce dependency on centralized isotope production facilities. As the demand for precision oncology diagnostics continues to rise, ARTMS is poised to leverage its technological moat to capture significant market share. Future strategic initiatives will likely involve further collaboration with pharmaceutical developers to streamline the integration of their isotope solutions into clinical trial workflows and routine diagnostic procedures.
See full ARTMS company page
